Canaccord Genuity Reiterates Buy on Taysha Gene Therapies, Maintains $13 Price Target
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst Whitney Ijem has reiterated a 'Buy' rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a price target of $13.
July 06, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity has reiterated a 'Buy' rating on Taysha Gene Therapies and maintained a price target of $13.
The reiteration of a 'Buy' rating by Canaccord Genuity, a reputable financial services firm, is a positive signal for Taysha Gene Therapies. The maintained price target of $13 also indicates a positive outlook for the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100